ArticlePloS one2013
Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 81 citations in OpenAlex.
- Dual-functional nanoparticle formulations for simultaneous intraocular pressure reduction and neuroprotection in glaucoma: a review.Nanomedicine (London, England) · 2026Review
- Nanotherapy for Neural Retinal Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Nanozymes for Treating Ocular Diseases.Advanced healthcare materials · 2025Review
- Cerium oxide nanoparticles attenuates fibrosis and inflammation in thyroid-associated ophthalmopathy via JNK pathway.Frontiers in molecular biosciences · 2025Article
- Ceria nanoparticles: biomedical applications and toxicity.Journal of Zhejiang University. Science. B · 2024Review
- Article
- Pegylated nanoceria: A versatile nanomaterial for noninvasive treatment of retinal diseases.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Review
- Antioxidant Properties of Cerium Oxide Nanoparticles Prevent Retinal Neovascular Alterations In Vitro and In Vivo.Antioxidants (Basel, Switzerland) · 2022Article
- Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.International journal of molecular sciences · 2021Review
- The Impact of Oxidative Stress on Blood-Retinal Barrier Physiology in Age-Related Macular Degeneration.Cells · 2021Review
- Cerium Oxide Nanoparticles (Nanoceria): Hopes in Soft Tissue Engineering.Molecules (Basel, Switzerland) · 2020Review
- An overview on recentAsian journal of pharmaceutical sciences · 2020Review
- Ceria Nanoparticles Mitigate the Iron Oxidative Toxicity of Human Retinal Pigment Epithelium.Cureus · 2020Article
- Article
- Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases.Frontiers in bioengineering and biotechnology · 2020Review
- Safety Assessment of Nanomaterials to Eyes: An Important but Neglected Issue.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Synthesis and biomedical applications of nanoceria, a redox active nanoparticle.Journal of nanobiotechnology · 2019Review
- Carboxylic acids accelerate acidic environment-mediated nanoceria dissolution.Nanotoxicology · 2019Article
- Antioxidant and toxicity studies of biosynthesized cerium oxide nanoparticles in rats.International journal of nanomedicine · 2019Article
- Nanoceria-loaded injectable hydrogels for potential age-related macular degeneration treatment.Journal of biomedical materials research. Part A · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Cerium oxide nanoparticles (nanoceria) possess catalytic and regenerative radical scavenging activities. The ability of nanoceria to maintain cellular redox balance makes them ideal candidates for treatment of retinal diseases whose development is tightly associated with oxidative damage. We have demonstrated that our stable water-dispersed nanoceria delay photoreceptor cell degeneration in rodent models and prevent pathological retinal neovascularization in vldlr mutant mice. The objectives of the current study were to determine the temporal and spatial distributions of nanoceria after a single intravitreal injection, and to determine if nanoceria had any toxic effects in healthy rat retinas. Using inductively-coupled plasma mass spectrometry (ICP-MS), we discovered that nanoceria were rapidly taken up by the retina and were preferentially retained in this tissue even after 120 days. We also did not observe any acute or long-term negative effects of nanoceria on retinal function or cytoarchitecture even after this long-term exposure. Because nanoceria are effective at low dosages, nontoxic and are retained in the retina for extended periods, we conclude that nanoceria are promising ophthalmic therapeutics for treating retinal diseases known to involve oxidative stress in their pathogeneses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.